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ABSTRACT
Vascular endothelial growth factors (VEGFs) are best known for their
involvement in orchestrating the development and maintenance of
the blood and lymphatic vascular systems. VEGFs are secreted by a
variety of cells and they bind to their cognate tyrosine kinase VEGF
receptors (VEGFRs) in endothelial cells to elicit various downstream
effects. In recent years, there has been tremendous progress in
elucidating different VEGF/VEGFR signaling functions in both the
blood and lymphatic vascular systems. Here, and in the accompanying
poster, we present key elements of the VEGF/VEGFR pathway and
highlight the classical and newly discovered functions of VEGF
signaling in blood and lymphatic vessel development and pathology.
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Introduction
The vascular circulatory system evolved to enable the shuttling of
nutrients, oxygen or waste products between various tissues,
employing networks of blood vessels and lymphatic vessels that
arise by the processes of angiogenesis and lymphangiogenesis,
respectively. Over the past few decades, vascular endothelial growth
factors (VEGFs) and their receptors (VEGFRs) have emerged as the
principal drivers of angiogenesis and lymphangiogenesis, and
hence the development and maintenance of both of these vascular
systems. The field of VEGF/VEGFR signaling was established by
seminal papers describing the functional role of VEGFA (which
was initially named as VPF, for vascular permeability factor) and
the identification of VEGFA as an endothelial growth factor
Wihuri Research Institute and Translational Cancer Biology Program, Biomedicum
Helsinki, University of Helsinki, Helsinki 00290, Finland.
*These authors contributed equally to this work
‡Author for correspondence (kari.alitalo@helsinki.fi)
S.K., 0000-0002-0719-1773; K.A., 0000-0002-7331-0902
1











(Leung et al., 1989; Senger et al., 1983). These discoveries were
followed by the identification of the receptor tyrosine kinases
VEGFR1 (FLT1), VEGFR2 (KDR/FLK1) and VEGFR3 (FLT4)
(Matthews et al., 1991; Pajusola et al., 1992; Shibuya et al., 1990;
Terman et al., 1991), which were later shown to bind to VEGFs.
Since then, a multitude of studies has provided insights into the
mechanisms and regulation of VEGF/VEGFR signaling.
As organ development and function relies heavily on the parallel
development and maintenance of organ-specific vascular systems,
understanding the role and contribution of VEGF/VEGFR signaling
to these processes is essential for furthering our understanding
of development. In addition, it is now clear that VEGF signaling
is essential for the physiological function of many tissues and
plays important roles in the pathogenesis of diseases such as
cardiovascular disease, cancer and ocular disease. Here and in the
accompanying poster, we provide an overview of VEGF/VEGFR
signaling system components and explain the roles of each signaling
axis in development and disease.
An overview of VEGFs and their receptors
In mammals, VEGFA is the prototype member of the VEGF family
of proteins, which also includes VEGFB, VEGFC, VEGFD and
placenta growth factor (PLGF) (Joukov et al., 1997; Leung et al.,
1989;Maglione et al., 1991; Olofsson et al., 1996; Park et al., 1994).
VEGFs are formed from antiparallel polypeptides that form a
cystine-knot homodimer covalently linked by two intermolecular
disulfide bonds. VEGFs have characteristic receptor-binding
patterns and they stimulate angiogenesis and lymphangiogenesis via
one or two of the three endothelial receptor tyrosine kinases
VEGFR1, VEGFR2 and VEGFR3 (Matthews et al., 1991; Pajusola
et al., 1992; Shibuya et al., 1990; Terman et al., 1991). VEGFRs
consist of seven immunoglobulin (Ig) homology domains that contain
the ligand-binding part and a split tyrosine kinase domain, which
transduces the growth factor signals. VEGFA signaling in blood
vascular endothelial cells is mediated predominantly via activation of
VEGFR2 (Simons et al., 2016). VEGFB, PLGF and VEGFA are
high-affinity ligands of VEGFR1, but because of the relatively weak
VEGFR1 kinase activity, this receptor serves as a negative regulator
ofVEGFA signaling by limiting the amount of free VEGFA available
for binding to VEGFR2 homodimers (Hiratsuka et al., 1998; Joukov
et al., 1997; Leung et al., 1989; Maglione et al., 1991; Olofsson et al.,
1996; Park et al., 1994). By contrast, VEGFC and VEGFD stimulate
VEGFR3 activation, which plays an indispensable role in
lymphangiogenesis (Tammela and Alitalo, 2010).
Alternative splicing and processing of VEGF familymembers
Multiple species of VEGFs that have different affinities for VEGFRs,
co-receptors and heparan sulfate (HS) proteoglycans can be generated
by alternative RNA splicing or proteolytic processing. In humans,
alternative RNA splicing results in the generation of the four
major VEGFA isoforms (VEGFA121, VEGFA165, VEGFA189 and
VEGFA206) that have different affinities for neuropilin co-receptors
and HS proteoglycans on the cell surface and in the pericellular
matrix (Houck et al., 1992; Leung et al., 1989). Additional splicing in
the last exon and programmed stop codon read-through can generate
further isoforms, which are of unknown significance (Harris et al.,
2012; Xin et al., 2016). The VEGFR1-specific ligands VEGFB and
PLGF are very similar in many respects; they exist as two major
isoforms that show differences in solubility, and HS and NRP1
binding (Migdal et al., 1998; Olofsson et al., 1996).
Most of the VEGFA isoforms are bound to HS on the cell surface
or in the extracellular matrix (ECM) (Houck et al., 1992).
This contributes to the generation of VEGFA gradients that are
important for the development and patterning of the vascular system.
The serine protease plasmin and a subset ofmatrixmetalloproteinases
can induce the release of proteolytically cleaved VEGFA from the
ECM; soluble VEGFA can thus be produced by both alternative
splicing and proteolytic cleavage (Houck et al., 1992; Lee et al., 2005;
Plouët et al., 1997). An excess of soluble VEGFA is also sequestered
by soluble VEGFR1 (sVEGFR1) that is generated from an
alternatively spliced VEGFR1 mRNA (Kendall and Thomas, 1993).
Whereas VEGFA isoforms are mainly formed through alternative
splicing, the different forms of VEGFC and VEGFD are generated
by proteolytic processing. VEGFC is synthesized as a precursor
in which the central VEGF homology domain (VHD) is flanked
by N- and C-terminal propeptides. Proteolytic removal of the
propeptides increases VEGFC affinity for VEGFR3, and the
resulting mature protein can also activate the major angiogenic
receptor VEGFR2 (Joukov et al., 1997). During its secretion,
VEGFC undergoes cleavage in the C-terminal region, resulting in
pro-VEGFC. The N-terminal cleavage that then results in full
activity of VEGFC is regulated by collagen- and calcium-binding
EGF domains 1 (CCBE1) protein and executed by a disintegrin
and metalloprotease with thrombospondin motifs-3 (ADAMTS3)
protease (Jeltsch et al., 2014; Le Guen et al., 2014; Roukens et al.,
2015). Specific proteases that activate VEGFD by cleavage of the
N-terminal propeptide are so far unknown, suggesting that VEGFD
has evolved to function in distinct angiogenic and lymphangiogenic
responses (Bower et al., 2017; Bui et al., 2016; McColl et al., 2003).
VEGF pathway activation mechanisms
Ligand-induced VEGFR homodimerization and activation
VEGF ligands bind to the Ig-like domains 1-3 of their cognate
VEGFRs, thereby inducing the activation of VEGFRs via
symmetrical homotypic interactions between their membrane-
proximal Ig-like domains 4-7 (Leppanen et al., 2013; Markovic-
Mueller et al., 2017; Yang et al., 2010). As an exception, VEGFB,
which is a weak agonist of VEGFR1, does not appear to interact
with domain 3 and cannot induce similar homotypic interactions
(Anisimov et al., 2013). Conservation of the ligand-binding sites and
the homotypic interactions provides the structural basis of VEGFR
heterodimerization (Leppanen et al., 2013; Markovic-Mueller et al.,
2017; Yang et al., 2010). VEGFRs can also form dimers in the
absence of ligand, but ligand binding changes transmembrane domain
conformation, thereby stimulating kinase domain phosphorylation
(Sarabipour et al., 2016). Of note, antibodies that block VEGFR
homotypic interactions, and hence VEGFR activation, provide
promising tools for the therapeutic modulation of VEGFR2 and
VEGFR3 activity (Kendrew et al., 2011; Tvorogov et al., 2010).
Heterodimerization of VEGFRs
VEGFRs can also heterodimerize, leading to slightly different
signaling outcomes. For example, ligand-stimulated VEGFR1/
VEGFR2 heterodimerization attenuates VEGFR2 phosphorylation,
but increases VEGFR1 signaling (Cudmore et al., 2012; Huang
et al., 2001). VEGFC, and apparently to some extent also VEGFA,
can stimulate VEGFR2/VEGFR3 heterodimerization in the tip cells
of angiogenic sprouts, presumably increasing angiogenic activity
(Dixelius et al., 2003; Nilsson et al., 2010).
VEGFA signaling can be modulated by VEGFB and PLGF
PLGF and VEGFB can induce signaling through VEGFR1 in
pericytes and in other cells (Eilken et al., 2017; Muramatsu et al.,
2010; Selvaraj et al., 2015; Shibuya and Claesson-Welsh, 2006) but,
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mechanistically, a more important feature of these ligands is that
their binding to VEGFR1 increases VEGFA availability for
VEGFR2 binding and activation (Hiratsuka et al., 1998; Kivela
et al., 2014; Park et al., 1994; Robciuc et al., 2016). PLGF and
VEGFA can also form heterodimers when expressed in the same
cells, which may further modulate VEGFA signaling through
VEGFR2 (Cao et al., 1996). In addition, although VEGFR1
deletion in embryos is lethal, the removal of only the VEGFR1
tyrosine kinase domain is compatible with vascular development,
suggesting that membrane-bound VEGFR1 can act as a decoy
receptor for VEGFA (Hiratsuka et al., 1998).
Neuropilin co-receptors and accessory molecules regulate VEGFR
signaling
A number of VEGF-interacting co-receptors and non-interacting
accessory molecules regulate the time course, subcellular localization
and amplitude of VEGFR signaling. The semaphorin receptor
neuropilin 1 (NRP1), for example, is also a VEGFR2 co-receptor,
and it regulates VEGFA-mediated endothelial permeability by
modulating VEGFR2 phosphorylation and downstream signaling
(Becker et al., 2005; Fantin et al., 2017; Soker et al., 1998). VEGFA,
VEGFR2 and NRP1 bind weakly to HS proteoglycans alone, but
show synergistic binding to HS proteoglycans when presented
together in various combinations. This increases VEGFA-stimulated
VEGFR2 activation and ERK1/2 phosphorylation in endothelial cells
(Teran and Nugent, 2015). NRP2 is an important co-receptor for
VEGFR3 in the lymphatic vasculature, and HS proteoglycans have
also been shown to contribute to VEGFC signaling (Johns et al.,
2016; Kärpänen et al., 2006; Xu et al., 2010).
Vascular endothelial (VE)-cadherin at endothelial cell-cell
junctions and integrin-ECM interactions modulate VEGFR2 and
VEGFR3 signaling in response to fluid flow-induced biomechanical
stimuli (Chen et al., 2010; Coon et al., 2015). Integrins have also been
shown to interact with VEGFR2 that is activated by matrix-bound
VEGFA isoforms, which increases VEGFR2 phosphorylation and
downstream signaling (Chen et al., 2010). The VEGFR2/integrin
association ismediated by the tetraspanin CD63 (Tugues et al., 2013).
Integrins can also promote ligand-independent VEGFR activation
upon cell adhesion to the ECM (Galvagni et al., 2010).
Intracellular trafficking of VEGF-VEGFR complexes modulates
their signaling. For example, growth factor-mediated activation of
VEGFRs induces ephrin B2-dependent endocytosis of the ligand-
receptor complexes, which is important for spatial control and full
activation of various downstream signaling pathways (Sawamiphak
et al., 2010; Wang et al., 2010). In particular, the deletion of Efnb2
decreases VEGFC-stimulated phosphorylation of VEGFR3, the
serine/threonine protein kinase AKT and the mitogen-activated
protein kinase ERK1/2, as well as VEGFA-stimulated VEGFR2
phosphorylation.
Signaling downstream of VEGFRs
Successful ligand-stimulated dimerization leads to the auto-
phosphorylation of specific tyrosine residues located in the
intracellular juxtamembrane domain, the kinase domain and the
C-terminal tail of VEGFRs. These phosphotyrosine residues
then serve as docking sites for downstream signaling
molecules that regulate cellular responses. Activated VEGFR2,
for example, is phosphorylated on multiple tyrosine residues, and
the phosphorylation results in biological responses such as
proliferation, migration, survival and permeability (reviewed by
Simons et al., 2016). Themajor phosphorylation sites in VEGFR2 are
Tyr951 in the kinase insert domain and Tyr1175 in the C-terminal
domain. Phosphorylated Tyr951 mediates TSAd adaptor protein-
dependent SRC tyrosine kinase activation, which in turn regulates
vascular permeability through VE-cadherin phosphorylation and
internalization (Li et al., 2016). By contrast, phosphorylated
Tyr1175 recruits PLCγ to the plasma membrane and triggers the
hydrolysis of phosphatidylinositol-4,5-bisphosphate to
diacylglycerol (DAG) and inositol 1,4,5-triphosphate [IP3;
Ins(1,4,5)P3] (Takahashi et al., 2001). This then activates the
ERK and Ca2+-signaling pathways, and regulates endothelial cell
proliferation and migration. Additional phosphorylation sites in
VEGFR2 have been reported, but their role is still unclear
(Matsumoto et al., 2005). For further details, the reader is referred
to a recent review (Simons et al., 2016).
Several phosphotyrosine residues have also been reported in
VEGFR1, although its kinase activity is low (apparently owing to a
repressor sequence in the juxtamembrane domain) and it does not
seem to promote ligand-stimulated cell migration or mitogenesis in
endothelial cells (Gille et al., 2000; Ito et al., 1998). However,
VEGFR1 is expressed in monocyte/macrophage-lineage cells and
its signaling promotes mobilization of macrophage lineage cells
from bone marrow and modulates the function of sensory nerves
(Muramatsu et al., 2010; Sawano et al., 2001; Selvaraj et al., 2015).
VEGFR3 is also phosphorylated following activation, leading to
downstream signaling events. In particular, it has been shown that
VEGFC-induced VEGFR3 activation leads to phosphorylation of the
serine/threonine kinases AKT and ERK, which promote lymphatic
endothelial cell (LEC) proliferation, migration and survival (Makinen
et al., 2001; Salameh et al., 2005).
VEGFR signaling in blood vessels
Angiogenesis, the formation of new blood vessels from pre-existing
ones, is mediated mainly by VEGFA/VEGFR2 signaling. In this
context, VEGFA induces endothelial proliferation, migration and
survival via activation of VEGFR2 and its downstream signal
transduction pathways. By contrast, VEGFR1, which has a higher
affinity for VEGFA but possesses weak tyrosine kinase activity, acts
as an anti-angiogenic decoy receptor on the endothelial cell surface
or in a soluble form (Shibuya and Claesson-Welsh, 2006). In line
with this, the VEGFR1-specific ligands VEGFB and PLGF do not,
in general, recapitulate many of the VEGFA effects (Gerber et al.,
1998). VEGFR3 is also expressed in angiogenic endothelial cells,
where it is important for the ‘tip cell’ phenotype of sprouting vessels
(Tammela et al., 2011, 2008). Furthermore, macrophage-derived
VEGFC, which acts as a ligand for VEGFR3, seems to participate in
the fusion of vessel sprouts during the development of the retinal
vasculature (Tammela et al., 2011).
Several insights into VEGF signaling have come from studies of
angiogenesis in the developing mouse retina. Retinal angiogenesis
follows a highly ordered sequence of events, which rely on
VEGFA/VEGFR2 signaling and on hypoxia-regulated growth
factor gradients formed by different VEGFA isoforms. Mice in
which only a single VEGFA isoform (VEGFA120, VEGFA164 or
VEGFA188) is expressed have distinct vascular phenotypes
(Stalmans et al., 2002). Guidance cues from the cell- and
matrix-bound VEGF isoforms provide spatial information on
where the vessels need to develop in specific patterns. Postnatal
deletion of Vegf or Vegfr2, or the disruption of their interaction, is
sufficient to arrest retinal vascular growth, whereas postnatal
deletion of Vegfr1 results in increased angiogenesis (Gerhardt
et al., 2003; Ho and Fong, 2015). Interestingly, postnatal deletion
of Vegfr3 increases VEGFR2 levels (Heinolainen et al., 2017;
Zarkada et al., 2015), resulting in hypersprouting and hyperbranching
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of the retinal vasculature (Tammela et al., 2011), which is mediated
by VEGFR2 (Zarkada et al., 2015).
In addition to regulating blood vessel formation, VEGF signaling
can control vessel permeability (Nagy et al., 2012). VEGFA-
induced blood vessel permeability, in particular, is crucial for
physiological and pathological processes. The binding of VEGFA
to VEGFR2 recruits the TSAd adapter protein complex, which
regulates VEGFA-induced activation of the tyrosine kinase Src and
vascular permeability (Li et al., 2016; Sun et al., 2012). Activation
of Src also regulates focal adhesion kinase-mediated cell-matrix
adhesion, contributing to the permeability effect (Chen et al., 2012).
By contrast, angiopoietin 1, which binds to and activates the
receptor Tie2 on endothelial cells, can suppress permeability via
Diaph-mediated sequestration of Src (Gavard et al., 2008).
Interestingly, it was recently shown that VEGFR3 is essential for
keeping VEGFR2 expression under control, thereby modulating
VEGFA/VEGFR2 signaling and hence vascular permeability in
blood vascular endothelial cells (Heinolainen et al., 2017).
VEGFR signaling in lymphatic vessels
The lymphatic vascular network consists of initial absorptive
lymphatic capillaries, which drain into pre-collectors that contain
valves but lack smooth muscle cell coverage, eventually ending up in
collecting lymphatic vessels, which are endowed with a continuous
basement membrane and smooth muscle cell coverage (Karaman
et al., 2017). Lymphangiogenesis – the growth of lymphatic vessels
from pre-existing ones – occurs mainly in response to VEGFC-
induced VEGFR3 activation (Karkkainen et al., 2004). VEGFA, in
addition to inducing angiogenesis, can also stimulate lymphatic
vessel expansion (Nagy et al., 2002; Wirzenius et al., 2007). Despite
its similarity to VEGFC, VEGFD is dispensable for developmental
lymphangiogenesis in mammals (Baldwin et al., 2005), although its
absence leads to somewhat decreased lymphatic vessel caliber in
the skin (Paquet-Fifield et al., 2013) and inhibition of facial
lymphangiogenesis in zebrafish (Bower et al., 2017).
The first lymphatic endothelial progenitors in mouse embryos
egress as streams of cells from the roof of the cardinal vein at
embryonic day (E) 10.25 (Hägerling et al., 2013). Alternative non-
venous lymphatic endothelial progenitors have also been suggested
to exist (Mahadevan et al., 2014), and this concept has been
corroborated by genetic lineage-tracing experiments (Klotz et al.,
2015; Martinez-Corral et al., 2015; Nicenboim et al., 2015;
Stanczuk et al., 2015). The essential role of VEGFC in inducing
the migration of LECs has been shown in Vegfc-deficient embryos,
where LECs fail to detach from the cardinal vein to form the dorsal
peripheral longitudinal lymphatic vessel (PLLV) and the ventral
primordial thoracic duct (pTD), which leads to embryonic lethality
between E15.5 and E17.5 (Hägerling et al., 2013; Karkkainen et al.,
2004). In contrast, mice with a Vegfr3 deletion die at around E10.5
due to defects in cardiovascular development (Dumont et al., 1998).
VEGFC/VEGFR3 signaling also plays a role in regulating the
remodeling and homeostasis of lymphatic vessels. For example,
VEGFC can induce lymphangiogenesis via VEGFR3 and enhance
contractions of collecting lymphatic vessels via their surrounding
smooth muscle cells (Jeltsch et al. 1997; Gogineni et al., 2013).
Recently, the matrix-binding adapter protein CCBE1 and the
ADAMTS3 metalloprotease were shown to be essential for
proteolytic activation of VEGFC, thereby potentiating its full range
of effects (Jeltsch et al., 2014; Roukens et al., 2015). It has also been
shown that VEGFR3 stimulation protects LECs from apoptosis and
induces their growth and migration (Makinen et al., 2001). In adult
mice, most lymphatic vessels are independent of VEGFC/VEGFR3
signaling, which is however necessary for the maintenance of the
absorptive intestinal lymphatic vessels (lacteals) and meningeal
lymphatic vessels (Antila et al., 2017; Nurmi et al., 2015).
VEGF signaling and its inhibition in disease
VEGF/VEGFR signaling has been implicated in pathogenesis of
several diseases. For example, VEGFA promotes angiogenesis,
disruption of the blood-retinal barrier, inflammation and vision
loss in individuals with ocular diseases such as retinopathy of
prematurity, diabetic retinopathy and the wet form of age-related
macular degeneration (Ferrara and Adamis, 2016). VEGFR1 and its
soluble form of VEGFR1 (sVEGFR1) act as endogenous inhibitors
of VEGFA/VEGFR2 signaling, thus VEGFR1 mis-regulation can
also participate in pathological processes. Indeed, epithelial sVEGFR1
expression has been claimed to contribute to the avascularity and
transparency of the cornea in the eye (Ambati et al., 2006). It has also
been shown that the placenta produces high levels of sVEGFR1 during
pregnancy, and the pathogenesis of pre-eclampsia during the last
trimester has been linked to sVEGFR1 neutralization of VEGFA and
PLGF (Koga et al., 2003; Maynard et al., 2003).
In addition to endothelial cells, VEGFs and VEGF receptors are
expressed in non-endothelial cells, including some tumor cells.
VEGFA secreted by tumor cells stimulates the proliferation and
survival of endothelial cells, leading to the formation of new blood
vessels, which promotes tumor expansion (reviewed by Ferrara and
Adamis, 2016). In part because of the excessive VEGFA levels
expressed by hypoxic tumor cells, tumor vessels are organized in
a chaotic fashion instead of the hierarchical branching pattern
found in normal vascular networks (reviewed by Jain, 2003).
The development and use of neutralizing antibodies to VEGFA
produced the first direct evidence that tumor growth depends on
angiogenesis and confirmed the importance of VEGFA in this
process (Kim et al., 1993). However, the benefit of monotherapy
directed to VEGFA is limited to some tumor types, and the therapy
in general does not prolong overall patient survival (Prenen et al.,
2013). Currently, vigorous clinical trial activity is focused mainly
on combination therapies, including the use of VEGF- and immune
checkpoint-neutralizing antibodies (Khan and Kerbel, 2018).
Although tumor-associated lymphatic vessels have been validated
as therapeutic targets for metastasis inhibition, antibodies against
VEGFR3 have so far been tested only in a phase I clinical trial
(Dieterich and Detmar, 2016).
Aberrant VEGF signaling has also been linked to several
pathological processes in the eye. Corneal transparency in the
eye depends on strict vascular demarcation; in healthy corneas,
neither blood nor lymphatic vessels cross the limbus, allowing the
cornea to maintain an avascular state (Beebe, 2008). Pathological
angiogenesis and lymphangiogenesis are associated with corneal
inflammation (Bock et al., 2013). VEGFC signaling controls the
development of Schlemm’s canal, which is a specialized hybrid
vessel structure that leads aqueous humor from the anterior
chamber of the eye into venous circulation, regulating intraocular
pressure (Aspelund et al., 2014; Park et al., 2014). Genetic deletion
of Vegfc or Vegfr3, or the use of VEGFR3 signaling blockers,
inhibit Schlemm’s canal development and function, whereas
VEGFC injection into the anterior chamber of the eye leads to
Schlemm’s canal expansion and decrease of intraocular pressure
(Aspelund et al., 2014).
The VEGF pathway has also been linked to lymphedema, which is
characterized by excessive accumulation of protein-rich extracellular
fluid in the interstitial space due to impaired lymphatic vessel
function. Primary lymphedema can be caused by a genetic disease,
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such as Nonne-Milroy disease, whereas secondary lymphedema is
commonly caused by filariasis (roundworm infection) in developing
countries and by complications of surgery in individuals with
cancer. Individuals with Nonne-Milroy disease have tyrosine
kinase-inactivating mutations in one VEGFR3 allele, and
heterozygous mutations in VEGFC are linked to a Milroy-like
primary lymphedema (Gordon et al., 2013; Irrthum et al., 2000;
Karkkainen et al., 2000). Moreover, mutations in the CCBE1 and
ADAMTS3 genes have been linked to Hennekam syndrome, which
also involves lymphedema (Alders et al., 2009; Brouillard et al.,
2017; Jha et al., 2017). Because of the key involvement of
VEGFC/VEGFR3 signaling in the pathogenesis of lymphedema, a
phase I clinical trial (NCT02994771) has been started, in which
VEGFC gene therapy is used to repair damaged lymphatic vessels
after lymphadenectomy in individuals with breast cancer who
developed lymphedema of the ipsilateral arm.
The recent discovery of lymphatic vessels in the meningeal
tissues surrounding the central nervous system (CNS) has raised
interest in their possible contribution to neurological diseases
(Aspelund et al., 2015; Louveau et al., 2015; Ma et al., 2017).
Of note, it has recently been demonstrated that meningeal lymphatic
vessels develop postnatally followingVEGFC expression by smooth-
muscle cells around the blood vessels, and that they retain VEGFR3
signaling dependence in adults (Antila et al., 2017). This suggests that
targeting the VEGFC pathway could provide a means of modulating
the function and drainage capacity of meningeal lymphatic vessels in
the prevention or treatment of neuropathological conditions.
Conclusions
During the past few decades, it has been established that angiogenesis
is essential for embryonic development and homeostasis in adults,
as well as for the progression of cancer and other diseases. More
recently, lymphangiogenesis was also shown to be essential for
embryonic development, and to be involved in many pathological
processes such as lymphedema, inflammatory diseases and tumor
metastasis. Our knowledge of the circulatory system in general
and of the molecular mechanisms controlling angiogenesis and
lymphangiogenesis has improved considerably due to progress
in the identification of regulatory molecules and markers specific
to the blood vascular and lymphatic endothelium. These studies
have highlighted the pivotal roles of the VEGFA/VEGFR2
and VEGFC/VEGFR3 signaling axes in angiogenesis and
lymphangiogenesis, respectively. In addition, it is now known
that multiple co-receptors and accessory molecules regulate the
signaling downstream of these crucial pathways. Despite these
achievements, there are still many intriguing questions to be
addressed and preliminary findings to be confirmed. For example, it
is becoming clear that VEGFR2 and VEGFR3 are not entirely
specific to blood or lymphatic vasculature, but function – in part
redundantly – in both systems. Although their signaling functions
seem to involve heterodimerization at the ligand and receptor levels,
it is not clear whether this is significant in vivo. In addition to the
co-receptors and accessory molecules presented here, there are
many other potential regulators of VEGFR signaling that need to
be mechanistically validated. Major disease-related issues concern
the improvement of anti-angiogenic therapy in cancer, and
possibilities to develop pro-angiogenic and -lymphangiogenic
therapies. The discovery of meningeal lymphatics vessels and
their dependence on VEGF signaling could provide therapeutic
approaches for the treatment of individuals suffering from
neurological diseases. Looking ahead, the resolution of these and
other issues require improved understanding of VEGFR function
and signaling during development and disease, which should
provide successful therapeutic targeting of the vascular system in an
expanding spectrum of human pathologies.
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